โšกYour ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

Study to Assess SLN124 in Patients With Polycythemia Vera

(SLN)

Sponsored by Silence Therapeutics plc

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...

Current Status

Active, Not Recruiting

Auto-verified from ClinicalTrials.gov

Verified Dec 19, 2025

Phase

Clinical Trial

Sponsor

Silence Therapeutics plc

Enrollment Target

65

Start Date

Jan 2023

๐Ÿ“Š
1 of 65 participants interested
2% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.

Who Can Participate

Inclusion Criteria

Male and female patients aged 18 years or older.
A confirmed diagnosis of PV according to the revised 2016 World Health Organization criteria:
Suitable phlebotomy history
Must agree to adhere to appropriate contraception requirements
Patients who are not receiving cytoreductive therapy must have been discontinued from any prior cytoreductive therapy for at least 24 weeks before dosing and have recovered from any adverse events due to cytoreductive therapy.
Patients receiving cytoreductive therapy with hydroxyurea, interferon, busulfan or ruxolitinib must have received a stable dose of cytoreductive therapy for at least 12 weeks before dosing and with no planned change in dose.
Patients must have had a dermatological examination within 6 months prior to screening.
Must have an Eastern Cooperative Oncology Group score of 0, 1, or 2.

Exclusion Criteria

Drug intolerance: 1. History of intolerance to oligonucleotides, or GalNAc, or any component

โ“ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

๐Ÿ“‹

Study Type

INTERVENTIONAL

๐Ÿ‘ฅ

Target Enrollment

65 participants

โšง

Gender

ALL

๐Ÿข

Sponsor

Silence Therapeutics plc

Study Locations

Choose your preferred location or select flexible during enrollment

Unknown

Hammond

Louisiana

Location available
View Hammond location page
Unknown

Buffalo

New York

Location available
View Buffalo location page
Unknown

New York

New York

Location available
View New York location page
Unknown

Columbus

Ohio

Location available
View Columbus location page
Unknown

Huntsville

Texas

Location available
View Huntsville location page

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

๐Ÿ”’ Secure ยท ๐Ÿฅ Expert Care

Find More Myeloproliferative Neoplasms Trials by City

Browse all myeloproliferative neoplasms clinical trials in these cities โ€” not just this study.

Looking for Polycythemia Vera Treatment in Ann Arbor?

Join others in Michigan exploring innovative treatment options through clinical research

Polycythemia Vera Treatment Options in Ann Arbor, Michigan

If you're searching for Polycythemia Vera treatment in Ann Arbor, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Ann Arbor, New York, Durham and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Polycythemia Vera. All study-related care is provided at no cost to participants.

Local Sites
3 locations in Michigan
Now Enrolling
Up to 65 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Polycythemia Vera?

Potential Benefits

  • โœ“Access to new treatment approaches before public availability
  • โœ“Close monitoring by experienced medical professionals
  • โœ“Study-related care provided at no cost
  • โœ“Contribute to medical research for Polycythemia Vera

What to Expect

  • โ†’Initial screening to determine eligibility
  • โ†’Regular check-ups and monitoring visits
  • โ†’Possible compensation for time and travel
  • โ†’You can withdraw at any time

Frequently Asked Questions About This Polycythemia Vera Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT05499013. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.